CRYO-CELL INTERNATIONAL, INC. Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
CRYO-CELL INTERNATIONAL, INC. (CCEL) had Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount of $49.00 thousand as of 2019-05-31, per its 10-Q filed 2019-07-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions · last filed 2019-07-15
- 2019-05-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $49.00K.
- 2016-08-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $0.00.
- 2016-05-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $0.00.
- 2012-08-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $401.00K.
| Period end | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount |
|---|---|
| 2019-05-31 | $49.00K 10-Q · filed 2019-07-15 |
| 2016-08-31 | $0.00 10-Q · filed 2016-10-17 |
| 2016-05-31 | $0.00 10-Q · filed 2016-07-11 |
| 2012-08-31 | $401.00K 10-Q · filed 2012-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |